Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors

Molecular Medicine

Volumn 18, Issue 9, 2012, Pages 1281-1291

  Ntoufa, Stavroula ^a,b   Vardi, Anna ^b   Papakonstantinou, Nikos ^b   Anagnostopoulos, Achilles ^b   Aleporou Marinou, Vassiliki ^a   Belessi, Chrysoula ^c   Ghia, Paolo ^d,e   Caligaris Cappio, Federico ^d,e   Muzio, Marta ^d   Stamatopoulos, Kostas ^b,f  

^a UNIVERSITY OF ATHENS   (Greece)

^b G PAPANICOLAOU HOSPITAL   (Greece)

^c Nikea General Hospital Athens   (Greece)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BREAKPOINT CLUSTER REGION PROTEIN; IMMUNOGLOBULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR;

APOPTOSIS; ARTICLE; CELL STIMULATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; IGHV GENE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MUTATOR GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANTIGENS, CD; CELL SURVIVAL; CLONE CELLS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; IMMUNOGLOBULIN HEAVY CHAINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIGANDS; LYMPHOCYTE ACTIVATION; MALE; NOD2 SIGNALING ADAPTOR PROTEIN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTORS, ANTIGEN, B-CELL; TOLL-LIKE RECEPTORS;

EID: 84870314626     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00480     Document Type: Article

References (51)

1. Chiorazzi N, Ferrarini M. (2010) Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood. 117:1781-91.
2. Chiorazzi N, Ferrarini M. (2003) B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu. Rev. Immunol. 21:841-94.
3. Stamatopoulos K, et al. (2007) Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 109:259-70.
4. Murray F, et al. (2008) Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 111:1524-33.
5. Bomben R, et al. (2009) Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. Br. J. Haematol. 144:492-506.
6. Fais F, et al. (1998) Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J. Clin. Invest. 102:1515-25.
7. Darzentas N, et al. (2010) A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence. Leukemia. 24:125-32.
8. Damle RN, et al. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 94:1840-47.
9. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 94:1848-54.
10. Chiorazzi N, Rai KR, Ferrarini M. (2005) Chronic lymphocytic leukemia. N. Engl. J. Med. 352:804-15.
11. Belessi C, Stamatopoulos K. (2010) Stereotyped B-cell receptors in chronic lymphocytic leukemia. In: Stamatopoulos K GP, Rosenquist R, et al. (ed.) WKHealth Books, Milan, Italy, pp. 119-34.
12. Lanemo Myhrinder A, et al. (2008) A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood. 111:3838-48.
13. Catera R, et al. (2008) Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol. Med. 14:665-74.
14. Chu CC, et al. (2008) Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood. 112:5122-9.
15. Seiler T, et al. (2009) Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. Blood. 114:3615-24.
16. Chu CC, et al. (2010) Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood. 115:3907-15.
17. Akira S, Uematsu S, Takeuchi O. (2006) Pathogen recognition and innate immunity. Cell. 124:783-801.
18. Janeway CA Jr, Medzhitov R. (2002) Innate immune recognition. Annu. Rev. Immunol. 20:197-216.
19. Kawai T, Akira S. (2005) Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 17:338-44.
20. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. (2006) Nod-like proteins in immunity, inflammation and disease. Nat. Immunol. 7:1250-7.
21. Bernasconi NL, Onai N, Lanzavecchia A. (2003) A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 101:4500-4.
22. Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A. (2003) The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood. 102:956-63.
23. Meyer-Bahlburg A, Khim S, Rawlings DJ. (2007) B cell intrinsic TLR signals amplify but are not required for humoral immunity. J. Exp. Med. 204:3095-101.
24. Ruprecht CR, Lanzavecchia A. (2006) Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur. J. Immunol. 36:810-6.
25. Petterson T, et al. (2011) Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and Toll-like receptors. J. Leukoc. Biol. 89:177-87.
26. Leadbetter EA, et al. (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 416:603-7.
27. Lau CM, et al. (2005) RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202:1171-7.
28. Poovassery JS, Vanden Bush TJ, Bishop GA. (2009) Antigen receptor signals rescue B cells from TLR tolerance. J. Immunol. 183:2974-83.
29. Grandjenette C, Kennel A, Faure GC, Bene MC, Feugier P. (2007) Expression of functional tolllike receptors by B-chronic lymphocytic leukemia cells. Haematologica. 92:1279-81.
30. Rozkova D, et al. (2010) Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation. Int. J. Cancer. 126:1132-43.
31. Muzio M, et al. (2009) Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br. J. Haematol. 144:507-16.
32. Arvaniti E, et al. (2011) Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenetic significance in specific subsets of patients. Haematologica. 96:1644-52.
33. Hallek M, et al. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 111:5446-56.
34. Lefranc MP, et al. (2009) IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 37: D1006-12.
35. Brochet X, Lefranc MP, Giudicelli V. (2008) IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36: W503-8.
36. Decker T, et al. (2000) Immunostimulatory CpGoligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood. 95:999-1006.
37. Ghiotto F, et al. (2004) Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J. Clin. Invest. 113:1008-16.
38. Shi Y, White D, He L, Miller RL, Spaner DE. (2007) Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res. 67:1823-31.
39. Longo PG, et al. (2007) The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 21:110-20.
40. Lanham S, et al. (2003) Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 101:1087-93.
41. Mockridge CI, et al. (2007) Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood. 109:4424-31.
42. Muzio M, et al. (2008) Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood. 112:188-95.
43. Ghia P, et al. (2005) Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood. 105:1678-85.
44. Potter KN, et al. (2006) Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia. Clin. Cancer Res. 12:1672-9.
45. Jang YJ, Stollar BD. (2003) Anti-DNA antibodies: aspects of structure and pathogenicity. Cell Mol. Life Sci. 60:309-20.
46. Kostareli E, et al. (2009) Molecular evidence for EBV and CMV persistence in a subset of patients with chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. Leukemia 23:919-24.
47. Sutton LA, et al. (2009) Extensive intraclonal diversification in a subgroup of chronic lymphocytic leukemia patients with stereotyped IGHV4-34 receptors: implications for ongoing interactions with antigen. Blood. 114:4460-68.
48. Messmer BT, et al. (2004) Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J. Exp. Med. 200:519-25.
49. Marincevic M, et al. (2010) High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors. Haematologica. 95:1519-25.
50. Marincevic M, et al. (2010) Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. Haematologica. 95:2072-9.
51. Spaner DE, Masellis A. (2007) Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia Leukemia. 21:53-60.